Rosenthal YS, Schwartz N, Sagy I, et al. - Biologic treatments induce a statistically and clinically significant reduction in the risk for developing psoriatic arthritis (PsA) in psoriasis patients. Based on this study’s findings, considering biologic medications is recommended for patients who present with significant risk factors for PsA at an earlier stage of treatment.

• In this retrospective cohort study, 1,326 patients with psoriasis were analyzed, including 663 who had received biologic treatment and 663 who had not.

• A statistically significant elevated risk for PsA in the control group vs the biologic treatment group was indicated by the Kaplan-Meier curve for the propensity score–matched groups.

• Using multivariable Cox regression, a significantly higher risk for PsA was seen in the control group vs the biologic treatment group within 10 years of follow-up (adjusted hazard ratio 1.39).